# Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer

Page: https://stenobird.com/podcast/the-uromigos-1214845/episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer
Text version: https://stenobird.com/podcast/the-uromigos-1214845/episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer.md
Podcast: [The Uromigos](https://stenobird.com/podcast/the-uromigos-1214845)
Published: 2026-05-31T18:30:00+00:00
Episode link: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-508-ASCO-2026-Plenary---PROTEUS-ADT---Apalutamide-in-high-risk-Localized-Prostate-Cancer-e3jja7d
Audio file: https://anchor.fm/s/13347ea8/podcast/play/120219309/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-19%2F424459091-44100-2-9da0f181e09c.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer
Duration seconds: 2380

## Resource

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-uromigos-1214845/episode-508-asco-2026-plenary-proteus-adt-apalutamide-in-high-risk-localized-prostate-cancer.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.